• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Viela Bio, Inc.

    3/15/21 9:12:58 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care
    Get the next $VIE alert in real time by email
    S-8 POS 1 d140140ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 15, 2021

    Registration No. 333-237383

    Registration No. 333-234179

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    FORM S-8 REGISTRATION STATEMENT NO. 333-237383

    FORM S-8 REGISTRATION STATEMENT NO. 333-234179

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    VIELA BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   82-4187338

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    One Medimmune Way

    First Floor, Area Two

    Gaithersburg, MD

      20878
    (Address of Principal Executive Offices)   (Zip Code)

    Amended and Restated 2018 Equity Incentive Plan

    (Full title of the plans)

    Paul W. Hoelscher

    Treasurer

    Viela Bio, Inc.

    One Medimmune Way

    First Floor, Area Two

    Gaithersburg, MD 20878

    (240) 558-0038

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Barbara L. Borden

    Rama Padmanabhan

    Cooley LLP

    4401 Eastgate Mall

    San Diego, California 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 relates to the following Registration Statements filed by Viela Bio, Inc. (the “Registrant” or the “Company”) on Form S-8 (collectively, the “Registration Statements”):

     

      •  

    Registration Statement No.  333-234179, filed with the Securities and Exchange Commission (the “SEC”) on October 11, 2019, relating to the registration of 4,668,910 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) for issuance under the Company’s Amended and Restated 2018 Equity Incentive Plan (the “Plan”); and

     

      •  

    Registration Statement No.  333-237383, filed with the SEC on March 25, 2020, relating to the registration of an additional 2,024,714 shares of Common Stock for issuance under the Plan.

    The Company is filing this Post-Effective Amendment No. 1 to the Registration Statements to withdraw and remove from registration any and all shares of Common Stock that remain unsold or otherwise unissued under the Registration Statements.

    On March 15, 2021, pursuant to the Agreement and Plan of Merger, dated as of January 31, 2021 (the “Merger Agreement”), by and among the Company, Horizon Therapeutics USA, Inc., a Delaware corporation (“Parent”), Teiripic Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and solely for purposes of Sections 6.7 and 9.12 of the Merger Agreement, Horizon Therapeutics plc, a public limited company organized under the laws of Ireland (“Ultimate Parent”), Purchaser merged with and into the Company, with the Company continuing as the surviving corporation and as an indirect wholly owned subsidiary of Ultimate Parent.

    As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, State of Maryland on March 15, 2021.

     

    VIELA BIO, INC.

    By:   /s/ Paul W. Hoelscher
      Paul W. Hoelscher
      Treasurer

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements.

    Get the next $VIE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

      GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve

      3/1/21 4:01:00 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

      -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur

      2/25/21 8:30:00 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viela Bio, Inc.

      SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)

      3/17/21 7:40:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      3/10/21 9:46:40 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      2/16/21 4:22:37 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    SEC Filings

    See more
    • SEC Form 15-12B filed by Viela Bio, Inc.

      15-12B - Viela Bio, Inc. (0001734517) (Filer)

      3/25/21 4:01:54 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:15:53 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:12:58 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viela Bio downgraded by Guggenheim

      Guggenheim downgraded Viela Bio from Buy to Neutral

      2/8/21 11:51:17 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush

      Wedbush downgraded Viela Bio from Outperform to Neutral

      2/8/21 7:28:49 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush with a new price target

      Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00

      2/8/21 7:26:43 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 5:13:43 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Tyrell Rivers

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:53:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Plc Astrazeneca

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:52:55 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care